Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcadia Biosciences (RKDA) Operating Margin (2016 - 2025)

Arcadia Biosciences' Operating Margin history spans 12 years, with the latest figure at 152.61% for Q4 2025.

  • For Q4 2025, Operating Margin rose 3481.0% year-over-year to 152.61%; the TTM value through Dec 2025 reached 51.42%, up 2085.0%, while the annual FY2025 figure was 51.46%, 2085.0% up from the prior year.
  • Operating Margin reached 152.61% in Q4 2025 per RKDA's latest filing, down from 88.48% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 151.61% in Q2 2024 to a low of 313.88% in Q1 2023.
  • Average Operating Margin over 5 years is 109.55%, with a median of 116.91% recorded in 2024.
  • The largest YoY upside for Operating Margin was 352391bps in 2021 against a maximum downside of -99266bps in 2021.
  • A 5-year view of Operating Margin shows it stood at 222.23% in 2021, then skyrocketed by 136bps to 80.14% in 2022, then crashed by -292bps to 153.54% in 2023, then dropped by -22bps to 187.42% in 2024, then increased by 19bps to 152.61% in 2025.
  • Per Business Quant, the three most recent readings for RKDA's Operating Margin are 152.61% (Q4 2025), 88.48% (Q3 2025), and 34.43% (Q2 2025).